GOURI injections
고우리주사 · Korean term
GOURI is an injectable from the Korean company Dexlevo, described as a liquid polycaprolactone (PCL) collagen stimulator. Early peer-reviewed studies of this exact product exist, including a 30-person facial study and a three-person eye-area pilot, but they had no comparison groups and cannot show how well it works or its long-term safety. Bruising and swelling have been reported. Its Korean approval status was not confirmed for this guide.
On this page
Overview

GOURI is the brand name of an injectable product made by Dexlevo, a company based in Seoul. It is described as a liquid collagen stimulator made from polycaprolactone (PCL), a biodegradable polymer [1] [4] [6]. A few peer-reviewed studies of this exact product have been published, but they are small and had no comparison groups. They cannot show how well it works or how safe it is over time. Its approval status in Korea could not be confirmed for this guide.
What it is
According to the company, GOURI contains no microparticles and is designed to spread through the deeper skin layer, with the aim of encouraging collagen production across the treated area [1]. These are the manufacturer's design claims. The studies found have not shown that it works this way in people. Other PCL products, such as fillers made of PCL microspheres, have a different form and may differ in use and risk. Do not treat them as interchangeable with GOURI unless the specific product has been checked.
What it involves
GOURI is given by injection. Published reports describe its use around the eyes, on the cheeks and in the upper arm [4] [5] [6]. No dose, schedule or technique has been verified for this guide. The treatment plan should come from the treating clinician.
Reasons to discuss it with a clinician and limits
- A 2026 study treated 30 adults on the face and followed them for six months. Some skin measurements changed, and most participants rated their skin as improved. There was no comparison group or blinded assessment, and the authors say the results do not prove the treatment caused the changes [6].
- In that study, the main outcomes named when the study was registered were not reported. Later instrument readings were left out because of concerns about equipment reliability. Dexlevo supplied the product, the paper discloses company support for publication fees, and three authors had received lecture fees from the company [6].
- A 2026 pilot study looked back at photos of three women treated around the eyes and measured changes in eyelid and under-eye shape. It had no comparison group, and the authors describe their explanations of how it works as hypotheses [5].
- The company also presented results at a 2026 conference. The trade report does not give the study size, design or follow-up [1].
- None of these reports shows that GOURI works better than other treatments, how long results last or whether it is safe over the long term.
- Treatment is optional. Before deciding, discuss your goals, the alternatives (including no treatment) and the limited evidence.
Risks and considerations
In the 30-person study, reported side effects included bruising, swelling and lingering pain after treatment. All of them cleared without specific treatment, and no serious problems were reported [6]. A separate 2026 case series described seven people whose bruising lasted much longer than usual, most often under the eyes. In some, it lasted weeks to months before treatment. All improved or cleared eventually [4]. Three of that paper's authors work for Dexlevo, and the company paid the publication fee [4]. The eye-area pilot did not report on side effects [5]. These studies are too small to show how often side effects happen or to rule out rarer problems.
For injectable fillers in general, the FDA lists accidental injection into a blood vessel as the most serious risk, which can cause tissue death, vision problems and stroke [3]. Whether and how often this applies to GOURI is not known from the sources found.
Recovery and follow-up
No reliable recovery schedule has been established for GOURI. For fillers in general, the FDA lists bruising, redness, swelling and pain as common short-term effects [3]. Because bruising that lasted weeks or months has been reported with this product [4], ask your clinician how they would follow up bruising that does not fade. The FDA advises urgent care for unusual pain, vision changes, white or blue-grey skin near the injection site, or signs of stroke after a filler injection [3].
Questions to ask
- What is the exact product name and approval number, and where can I check it with Korea's Ministry of Food and Drug Safety?
- Is the product approved for the area and purpose you propose?
- Is this the same product used in the published studies, and what did those studies show and not show?
- How often do you see prolonged bruising or swelling, and how would you manage it?
- Are there reasons this treatment may not suit me, such as pregnancy, a bleeding tendency or a scarring history?
Educational information. AI editorial and source checking are not clinical review. Checked 16 Nov 2026.
- Category
- Skin
- General estimate
- Not availableNo reviewed estimate exists. Clinic prices, when published, appear on each clinic profile.
Doctors who list gouri injections
No doctors documented for this procedure yet.
A doctor appears here only when their scope is documented for this procedure at an exact clinic location.
Clinics that list gouri injections
Offering evidence from each clinic’s own website. Availability and suitability need confirmation with the clinic.
No clinics list it yet.
Sources
Clinical references
- Dexlevo Showcases PCL Collagen Stimulator Data at IMCAS 2026 · Plastic Surgery Practice (MEDQOR), 23 March 2026 · Checked 16 Nov 2026
- 같은 주사인데 다른 규제…스킨부스터 시장 이중 트랙 이유는? (Same injection, different regulation: why the skin-booster market has a dual track) · Medical Times (Korea), 6 May 2026 · Checked 16 Nov 2026
- Dermal Fillers (Soft Tissue Fillers) · U.S. Food and Drug Administration · Checked 16 Nov 2026
- A Case Series of Rare Long-Term Bruising Following Injection of Liquid-Form Polycaprolactone: Mechanisms and Therapeutic Insights · Clinical, Cosmetic and Investigational Dermatology (Dove Press), 2026; vol. 19; DOI 10.2147/CCID.S571602; PMID 41869420 · Checked 16 Nov 2026
- Periorbital Structural and Functional Modulation Following Liquid-Type Polycaprolactone Treatment: A Pilot Study · Journal of Clinical Medicine (MDPI), 2 June 2026; 15(11):4303; DOI 10.3390/jcm15114303 · Checked 16 Nov 2026
- Skin Quality and Safety Following Liquid-Form Polycaprolactone for Facial Rejuvenation: A Prospective Single-Arm Study · Dermatology and Therapy (Springer), 23 October 2026; DOI 10.1007/s13555-026-01963-z · Checked 16 Nov 2026
- Catalogue source
- Source
This page is for research. It is not medical advice and is not a recommendation. Whether a treatment suits you, its risks and its cost need an individual consultation with a licensed doctor.
Online correction reports are not open yet.